全球化战略“换道”：华大智造剥离美国子公司CGI

Core Viewpoint - BGI Genomics is adjusting its global strategy by divesting its U.S. subsidiary Complete Genomics (CGI) for $50 million and granting exclusive licensing of its core technology to Swiss Rockets, marking a shift from product export to technology output [1][3][10] Financial Summary - The sale of CGI is expected to provide significant direct revenue and improve cash flow for BGI Genomics [2] - BGI Genomics anticipates a net loss of 221 million to 273 million yuan in 2025, a substantial reduction of 54.56% to 63.22% compared to 2024 [1] - The financial situation of CGI shows a total asset reduction from approximately 246.5 million yuan to 49.7 million yuan post-divestiture, with net assets dropping from 211.6 million yuan to 12.6 million yuan [5] Strategic Shift - The transaction is viewed as a strategic "change of path," allowing BGI Genomics to alleviate ongoing losses and leverage Swiss Rockets' local resources for compliant operations in North America [3][6] - The deal transforms volatile business operations into structured, guaranteed licensing income, reducing operational uncertainty while retaining strategic development space in North America [3][4] Market Context - The North American gene sequencing market is projected to grow at a compound annual growth rate (CAGR) of 15.2% from 2024 to 2030, with major players like Illumina and Thermo Fisher Scientific dominating the market [6] - The global gene sequencing market is expected to exceed $25 billion by 2025, with a CAGR of over 14% anticipated through 2030 [8] Regulatory Environment - The transaction is subject to shareholder approval and regulatory reviews, introducing uncertainties regarding its completion and potential revenue [10] - BGI Genomics' strategy aligns with national policies promoting the domestic development of high-throughput gene sequencing technologies [9]